View Single Post
  #2  
Old Sat Aug 2, 2008, 10:06 PM
Ruth Cuadra Ruth Cuadra is offline
Administrator
 
Join Date: Jul 2006
Location: Los Angeles, California
Posts: 616
Just to be clear, the European study did not implicate Revlimid in causing MDS to transform to AML. There were problems with the study design that did not produce enough comparative data to show sufficient benefit from lenalidomide to warrant the risks. Here is the key passage from the study's conclusions:
Therefore, the data provided were insufficient to demonstrate a favourable benefit/risk balance of lenalidomide in the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a 5q deletion with or without additional cytogenetic abnormalities, or an isolated deletion 5q cytogenetic abnormality...
Regards,
Ruth
__________________
Diagnosed AA 10/96, MDS/RA 6/98, MUD/BMT 10/6/98
Reply With Quote